ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
用户EK72UzpfRONs
1个月前
84
10
已完结
1. 系统已在2026-06-09 17:45:07对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/s2468-1253(22)00233-3
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2468125322002333
其他信息:
出版社: Elsevier BV
作者: Severine Vermeire; Bruce E Sands; Herbert Tilg; Zsolt Tulassay; Radoslaw Kempinski; Silvio Danese; Ivan Bunganič; Josianne Nitcheu; Julien Santo; Didier Scherrer; Sophie Biguenet; Hartmut J Ehrlich; Jean-Marc Steens; Paul Gineste; William J Sandborn
